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The operative mortality and morbidity of pancreaticoduodenectomy (PD) remain high.  We analyzed 
PD patientsʼ clinical characteristics and surgical outcomes and discuss how PD clinical outcomes could 
be improved.  We retrospectively reviewed the cases of 400 patients who underwent a PD between 
January 1998 and April 2014 at Okayama University Hospital,  a very-high-volume center.  We identi-
ﬁed and compared the clinical outcomes between two time periods (period 1: 1998-2006 vs. period 
2: 2007-2014).  The total postoperative mortality and major complication rates were 0.75  and 15.8 ,  
respectively,  and the median postoperative length of stay (LOS) was 32 days.  Subsequently,  patients 
who underwent a PD during period 2 had a signiﬁcantly shorter LOS than those who underwent a PD 
during period 1 (29 days vs.  38.5 days,  p＜0.001).  The incidence of mortality and major complications 
did not diﬀer between the two periods.  In our multivariate analysis,  period 1 was an independent fac-
tor associated with a long LOS (p＜0.001).  The improvement of the surgical procedure and periopera-
tive care might be related to the shorter LOS in period 2 and to the consistently maintained low mortal-
ity rate after PD.  The development of multimodal strategies to accelerate postoperative recovery may 
further improve PDʼs clinical outcomes.
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P ancreaticoduodenectomy (PD) is one of the most complex abdominal operations involving the 
pancreas,  duodenum,  and other organs.  A PD is 
performed to treat tumors on the head of the pancreas,  
malignant tumors involving the common bile duct and 
duodenal papilla,  or other diseases.  The operative 
technique,  surgical instruments,  and perioperative 
care have evolved considerably over the years;  
however,  the operative mortality and morbidity due to 
PD remain high,  even at high-volume centers.  The 
postoperative mortality after PD has been reported to 
be 2.8-3.5  in a Japanese nationwide survey [1].  
Nationwide surveys in Western countries suggested 
higher mortality rates of 6.4-8.4  [2-4].  Moreover,  
the overall morbidity rate after PD was 40.0  in 
another Japanese nationwide survey [5].
　 Here we retrospective reviewed the clinical charac-
Acta Med.  Okayama,  2016
Vol.  70,  No.  3,  pp.  197-203
CopyrightⒸ 2016 by Okayama University Medical School.
Original Article http ://escholarship.lib.okayama-u.ac.jp/amo/
Received January 27, 2016 ; accepted March 24, 2016.
＊Corresponding author. Phone : ＋81-86-223-7151; Fax : ＋81-86-221-8775
E-mail : twin1957yagi2000@yahoo.co.jp (T. Yagi)
Conﬂict of Interest Disclosures: No potential conﬂict of interest relevant 
to this article was reported.
teristics and surgical outcomes of patients who under-
went a PD at a single center,  and we discuss how the 
clinical outcomes of PD could be improved.
Materials and Methods
　 Patients. This study was approved by the 
Ethics Committee of Okayama University School of 
Medicine,  Dentistry and Pharmaceutical Sciences and 
Okayama University Hospital (approval no. 2035),  and 
conducted in accordance with the Declaration of 
Helsinki.  The need for informed consent was waived.  
We retrospectively reviewed the medical records of 
400 consecutive patients who underwent PD at 
Okayama University Hospital (Okayama,  Japan) in the 
17-year period from January 1998 to April 2014.
　 Clinical data. From our database,  the follow-
ing demographic and clinical data were collected as 
preoperative factors: age,  sex,  height,  weight,  body 
mass index (BMI),  American Society of Anesthe-
siologists (ASA) physical status,  laboratory values 
(total lymphocyte count,  albumin,  and cholesterol 
level),  comorbidities,  and disease etiology.  The ASA 
physical status was preoperatively evaluated by anes-
thesiologists.  Data regarding the surgical procedure,  
the type of PD,  operative time,  and amount of blood 
loss were recorded as operative factors.  The postop-
erative factors were as follows: postoperative mortal-
ity,  morbidity,  and length of stay (LOS).  The postop-
erative morbidity was assessed by using the Clavien-
Dindo classiﬁcation,  according to major complications 
deﬁned as Clavien grade 3 [6].  Pancreatic ﬁstula 
(PF) and delayed gastric emptying (DGE) were evalu-
ated according to the International Study Group of 
Pancreatic Surgery guidelines,  and classiﬁed into 
three categories (grades A,  B,  and C) [7,  8].
　 We identiﬁed the clinical outcomes and compared 
them between two time periods (period 1: 1998-2006 
vs. period 2: 2007-2014).  We assessed the impact of 
prognostic factors associated with a long LOS by 
performing a multivariate analysis.
　 Surgical procedures. The details of the surgi-
cal techniques were as described [9].  In patients with 
malignant disease,  a classic PD or subtotal stomach-
preserving PD (SSPPD) with D2 lymph node dissec-
tion was performed.  Lymph nodes from the following 
areas were removed: hepatoduodenal ligament,  cir-
cumferentially around the common hepatic artery,  and 
the right-half circumference of the superior mesenteric 
artery.  Vascular reconstruction,  including portal vein 
reconstruction,  was performed in cases of advanced 
malignancy.
　 In patients with benign disease,  a pylorus-preserv-
ing PD (PPPD) was performed.  The basic recon-
struction of the digestive system was performed 
according to a modiﬁcation of the method described by 
Child [10].  The pancreatojejunostomy was performed 
by means of a duct-to-mucosa,  end-to-side pancreatoje-
junostomy.  An external drainage catheter was used as 
a stent for PD,  if necessary.  An end-to-side hepatoje-
junostomy was performed through a one-layer anasto-
mosis 10cm distal to the pancreatojejunostomy.  A 
duodenojejunostomy or gastrojejunostomy was per-
formed by means of a two-layer anastomosis 50cm 
distal to the hepatojejunostomy.  A Braun anastomosis 
was also added.
　 To prevent postoperative pseudoaneurysms after 
PD,  an omental ﬂap placement over splanchnic vessels 
was performed from 2003 onward [9].  From 1998 to 
2006,  an open drainage system was employed by using 
12-mm silicone Penrose drains (Kaneka,  Osaka,  
Japan).  From 2007 to the present,  a closed drainage 
system was used with 19- or 24-Fr BLAKE silicone 
drains (Johnson & Johnson,  Somerville,  NJ,  USA).
　 Concerning the type of operations,  a classic PD 
was usually performed for pancreatic cancer; however,  
from 2007,  the Hospitalʼs standard surgical procedure 
for malignant diseases was changed to SSPPD.  In 
addition,  the reconstruction of the duodenojejunos-
tomy or gastrojejunostomy was made through a post-
colic route between 1998 and 2006,  but was changed 
to an antecolic route from 2007 [11].
　 Statistical analyses. JMP version 10 software 
(SAS Institute,  Cary,  NC) was used for the statisti-
cal analyses.  Data are presented as mean,  median,  
and standard deviation (SD) for continuous variables.  
Categorical data are presented as proportions.  
Diﬀerences between groups were assessed by using the 
Mann-Whitney U-test for continuous variables,  and 
Fisherʼs exact test or χ2-test for categorical variables.  
To investigate the impact of prognostic factors associ-
ated with a long LOS,  we used a logistic regression 
model for univariate and multivariate analyses,  and we 
calculated odds ratios (ORs) and 95  conﬁdence 
intervals (95  Cis).  A p-value of＜0.05 was considered 
signiﬁcant.
198 Acta Med.  Okayama　Vol.  70,  No.  3Takagi et al.
Results
　 The annual volume of PD cases between 1998 and 
2013 at Okayama University Hospital is shown in 
Fig.  1.  The volume of PD cases rapidly increased 
after 2006.  During period 1 (1998-2006),  120 PDs 
were performed (mean,  13.3 cases per year).  During 
period 2 (2007-2014),  280 PDs were performed 
(mean,  38.7 cases per year).
　 The demographic and clinicopathological factors of 
the patients who underwent a PD are listed in 
Table 1.  The study population consisted of 242 men 
(60.5 ) and 158 women (39.5 ) with a mean age of 
65.2±14.4 years.  Most of the patients (90.5 ) had 
an ASA physical status of 1 or 2.  The laboratory 
values,  comorbidities,  and disease etiologies are also 
shown in Table 1.  The most common pathological 
indication for PD was pancreatic adenocarcinoma 
(40.8 ).  The age,  sex distribution,  body composi-
tion,  and ASA status of patients were not signiﬁ-
cantly diﬀerent between the two periods.
　 Concerning comorbidities,  the proportion of patients 
with hypertension was signiﬁcantly increased in 
period 2.  The etiology of diseases was also signiﬁ-
cantly diﬀerent between the two periods (p＝0.009).  
In period 1,  there were no patients with duodenal 
adenocarcinoma or pancreatic neuroendocrine tumor,  
and the proportion of patients with either of those 
diseases was increased in period 2.
　 Concerning operative procedures,  the following 
data were revealed for the entire patient population:  
PPPD (25.5 ),  SSPPD (62.5 ),  and PD (12.0 ).  
The rate of vascular reconstruction was 27.0 .  The 
mean operative time was 450±94.2min,  and the mean 
blood loss was 699±725ml.  Signiﬁcant diﬀerences 
between the two periods were observed in the type of 
PD (p＜0.001),  rate of vascular reconstruction (p＝
0.002),  operative time (p＝0.002),  and blood loss (p＜
0.001).  The operative time and blood loss were sig-
niﬁcantly decreased in period 2.
　 The mortality and major complication rates for all 
400 patients in this study were 0.75  and 15.8 ,  
respectively.  The rate of PF and DGE (grade B or C) 
were 34.3  and 19.5 ,  respectively.  The median 
LOS was 32 days (interquartile range,  25-42 days).  
The incidence of mortality and major complications did 
not diﬀer signiﬁcantly between the two periods.  The 
rate of PF was essentially the same for both periods,  
whereas the rate of DGE was signiﬁcantly decreased 
in period 2 (28.3  in period 1 vs. 15.7  in period 2,  
p＝0.004).  The patients who underwent a PD during 
period 2 had a signiﬁcantly shorter LOS than those 
who underwent a PD during period 1 (38.5 days in 
period 1 vs. 29 days in period 2,  p＜0.001).
　 Table 2 shows the results of the univariate and 
multivariate analyses performed to identify prognostic 
factors associated with a long LOS (＞30 days) after 
PD.  In the univariate analysis,  seven variables were 
independent predictors.  In the multivariate analysis,  
six variables were signiﬁcant prognostic factors:  
period 1 (p＜0.001),  hypertension (p＝0.015),  opera-
tive time (p＝0.043),  presence of major complications 
(p＜0.001),  presence of PF (p＜0.001),  and presence 
of DGE (p＜0.001).  Preoperative factors other than 
hypertension and operative factors other than opera-
tive time were not signiﬁcant in this study.
Discussion
　 This retrospective study shows the clinical charac-
teristics and surgical outcomes after PD in a single-
institution series of 400 patients over a 17-year 
period.  The results demonstrated that the annual 
volume of PD cases increased over the past decade,  
and that the mortality rate was extremely low even 
when compared with a Japanese nationwide survey 
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Fig. 1　 Annual volume of pancreaticoduodenectomy (PD) cases 
between 1998 and 2013 at Okayama University Hospital.
[1].  In addition,  the postoperative LOS became sig-
niﬁcantly shorter.  This ﬁnding is supported by those 
of previous reports,  in which a higher hospital case 
volume was related to lower in-hospital mortality and 
a shorter LOS [1,  12,  13].
　 At the single very-high-volume center examined,  
the annual volume of PD cases increased from 1998 to 
2013 (Fig.  1).  The mean number of PD cases during 
period 2 was 2.9 times higher than that during 
period 1.  This is because in Japan the surgical indica-
tions for PD have been expanded to benign tumors 
such as intraductal papillary mucinous neoplasms 
[14-16] or pancreatic neuroendocrine tumors [17,  
18],  and the procedure has been centralized.
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Table 1　 Demographic and clinicopathological factors of the 400 patients who underwent a pancreaticoduodenectomy at during the 








　Mean age (yrs)＊ 65.2±11.4 64.7±10.1 65.5±11.9 0.20
　Sex ratio (men/women)† 242/158 67/53 175/105 0.21
　Height (m)＊ 1.60±0.09 1.59±0.09 1.60±0.09 0.40
　Weight (kg)＊ 56.1±10.6 54.8±9.9 56.5±10.8 0.38
　BMI (kg/m2)＊ 21.8±3.2 21.6±3.0 21.9±3.3 0.50
ASA physical status†
　Grades 1-2/3-4 362/38 110/10 252/28 0.60
Laboratory values＊
　TLC (/mm3)‡ 1,628±589 1,575±623 1,650±574 0.09
　Alb (g/dl)§ 4.0±0.48 3.9±0.48 4.0±0.48 0.006
　T-cho (mg/dl)¶ 191±51.8 184±50.1 194±52.3 0.03
Comorbidity†
　Hypertension 143 30 113 0.003
　Diabetes 107 33  74 0.82
　Hyperlipidemia  93 21  72 0.08
Etiology of disease†
　Pancreatic adenocarcinoma 163 (40.8) 50 113 0.009
　Bile duct carcinoma 48 (12.0) 19  29
　Ampullary adenocarcinoma 50 (12.5) 16  34
　Duodenal adenocarcinoma 14 (3.5)  0  14
　IPMN 66 (16.5) 24  42
　PNET 17 (4.2)  0  17
　Others 42 (10.5) 11  31
Operative factors
　PPPD/SSPPD/PD† 102/250/102 24/63/33 78/187/15 ＜0.001
　Vascular reconstruction (%)† 108 (27.0) 45 (37.5) 63 (22.5) 0.002
　Operative time (min)＊ 450±94.2 475±94.4 440±92.4 0.002
　Blood loss (ml)＊ 699±725 990±841 574±631 ＜0.001
Postoperative factors
　Mortality (%)† 3 (0.75)  0 3 (1.07) 0.26
　Major complications (%)† 63 (15.8) 21 (17.5) 42 (15.0) 0.53
　PF (grades B-C,  %)† 137 (34.3) 39 (32.5) 98 (35.0) 0.63
　DGE (grades B-C,  %)† 78 (19.5) 34 (28.3) 44 (15.7) 0.004
　Median length of stay＊ 32 (25-42) 38.5 (29-48) 29 (23-38) ＜0.001
＊Mann-Whitney U-test.  †Fisherʼs exact test or χ2-test.  ‡Data of three patients were missing.  §Data of two patients were missing.  ¶Data 
of 11 patients were missing.
Values are mean±SD,  n (%),  or median (interquartile range),  unless otherwise indicated.  BMI,  body mass index; ASA,  American Society 
of Anesthesiologists; TLC,  total lymphocyte count; Alb,  albumin; T-cho,  total cholesterol; IPMN,  intraductal papillary mucinous 
neoplasm; PNET,  pancreatic neuroendocrine tumor; PPPD,  pylorus-preserving pancreaticoduodenectomy; SSPPD,  subtotal stomach-
preserving pancreaticoduodenectomy; PD,  pancreaticoduodenectomy; PF,  pancreatic ﬁstula; DGE,  delayed gastric emptying.
　 Among the 400 PD cases reviewed herein,  there 
were three cases (0.75 ) of in-hospital mortality.  
This mortality rate is lower than that in other very-
high-volume centers (＞28 PDs per year) in Japan 
(1.4 ) [1].  The causes of death were pseudoaneu-
rysm rupture (n＝1) and acute respiratory distress 
syndrome (n＝2).  From 2011 to the present,  a 
PD-related mortality rate of 0  has been maintained.  
The incidence of postoperative major complications 
was 15.8 ,  which is equal to that in a previous 
report [19].
　 The median LOS was 32 days,  and the mean LOS 
from 2011 to 2013 was 31.7±11.5 days,  which is 
much longer than that in Western countries (7-21 
days) [8].  Even in very-high-volume hospitals in Japan,  
the mean LOS after a PD was 32.8±19.2 days [1];  
thus,  the LOS at our institution was similar to that in 
other very-high-volume centers in the country.
　 With regard to comparisons between the two peri-
ods,  the rates of DGE and LOS were both signiﬁ-
cantly decreased in period 2; however,  the rates of 
major complications and PF remained the same from 
period 1 to period 2.  Major complications occurred at 
a constant rate after PD,  which is one of the most 
complex and highly invasive operations; however,  in 
the last 3 years of the study period,  the rate of major 
complications was 10.1  and had gradually decreased.  
Concerning PF,  its presence can now be more accu-
rately evaluated after standard diagnostic criteria 
were established in 2005 [7],  and this might be 
related to the absence of a decrease in PF in period 2.  
We have been making eﬀorts aimed at further improv-
ing the outcomes as mentioned below.
　 Our multivariate analysis revealed that period 1 
was an independent factor related to a long LOS 
(＞30 days) after PD (Table 2).  The incidences of 
major complications,  the presence of PF and DGE,  
hypertension,  and operative time were signiﬁcantly 
associated with a long LOS.  These results suggest 
that decreased postoperative complications and opera-
tive time contributed to shortening of the LOS.
　 To improve clinical outcomes,  several changes in 
surgical procedure have been applied at our institution 
on the basis of the available evidence.  The placement 
of an omental ﬂap over splanchnic vessels could be an 
eﬃcient surgical procedure to prevent postoperative 
pseudoaneurysms after PD [9].  Changes in the drain 
system,  the disconnection line of the stomach,  and the 
route of duodenojejunostomy or gastrojejunostomy 
were applied in 2007,  and these might have contrib-
uted to the improvement of clinical outcomes.  In fact,  
the development of stylized surgical procedures and 
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Table 2　 Univariate and multivariate analysis of prognostic factors associated with a long postoperative length of stay (＞30 days)
Univariate analysis Multivariate analysis
Variable No. patients(n＝400) OR 95% CI p-value
＊ OR 95% CI p-value＊
Period 1 (vs. period 2) 120 3.46 2.18-5.59 ＜0.001 4.80 2.75-8.60 ＜0.001
Sex (men) 242 1.38 0.93-2.07 0.11
Age ( 70 yrs) 157 1.39 0.93-2.09 0.11
BMI ( 25 kg/m2)  58 1.02 0.58-1.79 0.94
ASA ( grade 3)  38 0.69 0.35-1.36 0.28
Hypertension 143 1.64 1.09-2.49 0.02 1.87 1.13-3.12 0.015
Diabetes 107 0.79 0.50-1.22 0.29
Etiology of disease (malignancy) 280 1.19 0.77-1.82 0.43
PPPD (vs. SSPPD/PD) 102 1.11 0.71-1.74 0.66
Vascular reconstruction 108 0.94 0.60-1.46 0.78
Operative time ( 420 min) 142 2.02 1.33-3.09 0.001 1.74 1.02-3.01 0.043
Blood loss ( 1,000 ml)  86 2.02 1.23-3.35 0.005 1.10 0.56-2.14 0.78
Major complications  63 7.88 3.85-18.4 ＜0.001 6.20 2.77-15.5 ＜0.001
PF (grades B-C) 137 5.06 3.20-8.20 ＜0.001 5.93 3.52-10.2 ＜0.001
DGE (grades B-C)  78 3.43 1.99-6.15 ＜0.001 2.40 1.26-4.71 ＜0.001
＊Logistic regression model.  BMI,  body mass index; ASA,  American Society of Anesthesiologists; PPPD,  pylorus-preserving 
pancreaticoduodenectomy; SSPPD,  subtotal stomach-preserving pancreaticoduodenectomy; PD,  pancreaticoduodenectomy; PF,  pan-
creatic ﬁstula; DGE,  delayed gastric emptying; OR,  odds ratio; CI,  conﬁdence interval.
techniques resulted in the shortening of the operative 
time and the reduction of blood loss in period 2.
　 Strategies for perioperative care such as nutri-
tional treatment and exercise therapy may improve the 
postoperative outcomes after PD.  The Enhanced 
Recovery After Surgery (ERAS) program and the 
Fast-Track recovery program have been widely used,  
especially in colorectal surgery; these are multimodal 
perioperative management programs designed to 
achieve early recovery for patients undergoing major 
surgery [20-23].  Similarly,  guidelines for perioper-
ative care for PD are provided by the ERAS Society 
[24].  In these guidelines,  the available evidence is 
summarized and recommendations are given regarding 
27 perioperative care items.  The ERAS program may 
be eﬀective in the perioperative management for PD.
　 Despite our important ﬁndings,  there are a few 
limitations to the present study.  It was a retrospec-
tive,  single-center analysis,  and there thus may be a 
potential selection bias concerning the patients indi-
cated for PD.  Second,  the number of patients was 
small.  The clinical outcomes may also have been 
inﬂuenced by the hospital volume,  surgeon volume,  
hospital training status,  hospital compliance,  surgical 
instruments,  and surgical procedures [5].  How these 
variables aﬀected the mortality,  morbidity,  and LOS 
should be investigated in a future study.
　 In conclusion,  the improvement of surgical proce-
dures and perioperative care might be related to a 
shorter LOS and maintaining a low mortality rate 
after PD.  With the aim to further improve clinical 
outcomes,  we are now performing a randomized con-
trolled trial to investigate the eﬃciency of an ERAS 
protocol after PD (UMIN 000014068).
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